2,3,6-三氯吡啶 | 6515-09-9

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,3,6-三氯吡啶
• 中文别名: 三氯吡啶
• 英文名称: 2,3,6-trichloropyridine
• 英文别名: 2,3,6-Trichlor-pyridin
• CAS: 6515-09-9
• 化学式: C₅H₂Cl₃N
• mdl: MFCD00463516
• 分子量: 182.437
• InChiKey: GPAKJVMKNDXBHH-UHFFFAOYSA-N

物化性质

• 熔点：
  66-67 °C
• 沸点：
  300.44°C (rough estimate)
• 密度：
  1.8041 (rough estimate)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,3,6-Trichloropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,3,6-Trichloropyridine
CAS number: 6515-09-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H2Cl3N
Molecular weight: 182.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3,6-三氯吡啶 在 sodium hydroxide 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 1.0h， 以34%的产率得到3,6-dichloropyridin-2(1H)-one
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE LA DIHYDROOROTATE DÉSHYDROGÉNASE

  摘要：

  本文披露了一种通过调节DHODH来治疗受影响的疾病、紊乱或医疗状况的化合物、组合物和方法。这些化合物的实施例由以下的化学式(I)和化学式(II)表示：其中R1、R2、R3、R4、R5、R6、R7、R8、X1、X2、X3、X4、Y和Z在此定义。

  公开号：

  WO2021156787A1
• 作为产物：
  描述：

  2,6-二氯吡啶 在 氯 、 甲烷 、 copper dichloride 作用下， 以 水 为溶剂， 380.0~400.0 ℃ 、100.0 kPa 条件下， 反应 5.0h， 生成 2,3,6-三氯吡啶
  参考文献：
  名称：

  一种2,3,6-三氯吡啶的合成方法

  摘要：

  本发明公开了一种2，3，6‑三氯吡啶的合成方法，属于化工领域，以2，6‑二氯吡啶与氯气为原料，将2，6‑二氯吡啶气体和氯气混合后通入装有活性炭负载型催化剂的固定床反应器，在活性炭负载型催化剂的作用下生成2，3，6‑三氯吡啶；所述的活性炭负载型催化剂以AlCl3、NiCl2、CuCl2、FeCl3、CaCl2、BaCl2、MgCl2、CoCl2和LaCl2中的一种或多种为活性组分，以活性炭为载体；利用上述催化剂，以2，6‑二氯吡啶和氯气为原料，在无毒无害的催化剂的作用下一步生成2，3，6‑三氯吡啶，该方法转化率高，选择性好，无污染。

  公开号：

  CN107759512A
• 作为试剂：
  描述：

  、 sodium hydroxide 、 2,3,5,6-tetrachloro-4-hydrazinopyridine 、 水 在 二氯甲烷 、 2,3,6-三氯吡啶 作用下， 以 异丙醇 为溶剂， 反应 2.0h， 生成 2,3,6-三氯吡啶
  参考文献：
  名称：

  Method for preparing 2,5-dihalo- and 2,5,6-trihalopyridines

  摘要：

  一种制备2,5-二卤和2,5,6-三卤吡啶的方法，其对应于以下公式：##SPC1## 其中每个X独立地表示氯、氟或溴，R表示氢、氯、氟或溴，包括将以下任一公式的卤酰肼吡啶：##SPC2## 与过量的水溶性碱金属氢氧化物在以下反应介质的存在下反应：1至4个碳原子的低级脂肪醇和2至4个碳原子的低级烷基乙二醇。

  公开号：

  US03947457A1

文献信息

• 嘧啶及其变体、及其用途
  申请人：传入制药公司

  公开号：CN108779119B

  公开（公告）日：2022-02-08

  本公开提供了式1的嘧啶化合物及其用途，例如用于潜在治疗与P2X嘌呤受体相关的疾病。在某些方面中，本公开提供了可用于例如潜在治疗内脏器官、心血管和疼痛相关的疾病、病症和紊乱的P2X3和/或P2X2/3拮抗剂。
• [EN] HOMOGENEOUS PROCESS FOR HYDRODEHALOGENATING HALOGENATED HETEROARYL COMPOUNDS<br/>[FR] PROCÉDÉ HOMOGÈNE D'HYDRODÉHALOGÉNATION DE COMPOSÉS HÉTÉROARYLES HALOGÉNÉS
  申请人：JOHNSON MATTHEY PLC

  公开号：WO2017085476A1

  公开（公告）日：2017-05-26

  The present invention provides a homogeneous process for hydrodehalogenating a halo-substituted C3-C20 heteroaryl starting material to form a non-halogenated C3-C20 heteroaryl product and/or a halo- substituted C3-C20 heteroaryl product, wherein the halo-substituted C3-C20 heteroaryl product has at least one less halogen substituents than the halo-substituted C3-C20 heteroaryl starting material, the process comprising the step of hydrogenating the halo-substituted C3-C20 heteroaryl starting material in the presence of a rhodium or ruthenium complex, molecular hydrogen, a base and a solvent, wherein the process is carried out in a monophasic solvent system and the molar ratio of base to each halogen substituent to be removed is at least 1 :1.

  本发明提供了一种均相过程，用于将含卤代的C3-C20杂环起始物水合脱卤，形成非卤代的C3-C20杂环产物和/或含卤代的C3-C20杂环产物，其中所述含卤代的C3-C20杂环产物比含卤代的C3-C20杂环起始物至少少一个卤素取代基，所述过程包括在铑或钌配合物、分子氢、碱和溶剂存在下水合脱卤所述含卤代的C3-C20杂环起始物的步骤，其中所述过程在单相溶剂体系中进行，碱与每个待去除的卤素取代基的摩尔比至少为1:1。
• [EN] FUSED IMIDAZOLE COMPOUNDS<br/>[FR] COMPOSÉS D'IMIDAZOLE CONDENSÉS
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2015115673A1

  公开（公告）日：2015-08-06

  The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) and act as GABAA α5 negative allosteric modulators (GABAA α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA α5 such as Alzheimer's disease.

  本发明提供了由式(I)表示的化合物，其药学上可接受的盐，N-氧化物，溶剂合物或前药（其中字符如描述中所定义）。由式(I)表示的化合物对γ-氨基丁酸A受体亚单位α5（GABAA α5）具有亲和力和选择性，并作为GABAA α5负向变构调节剂（GABAA α5 NAM）发挥作用，因此它们在预防和/或治疗与GABAA α5相关的疾病，如阿尔茨海默病中是有用的。
• Discovery and <i>In Vivo</i> Anti-inflammatory Activity Evaluation of a Novel Non-peptidyl Non-covalent Cathepsin C Inhibitor
  作者：Xing Chen、Yaoyao Yan、Zhaoyan Zhang、Faming Zhang、Mingming Liu、Leran Du、Haixia Zhang、Xiaobao Shen、Dahai Zhao、Jing Bo Shi、Xinhua Liu

  DOI：10.1021/acs.jmedchem.1c00104

  日期：2021.8.26

  Cathepsin C (Cat C) participates in inflammation and immune regulation by affecting the activation of neutrophil serine proteases (NSPs). Therefore, cathepsin C is an attractive target for treatment of NSP-related inflammatory diseases. Here, the complete discovery process of the first potent “non-peptidyl non-covalent cathepsin C inhibitor” was described with hit finding, structure optimization, and

  组织蛋白酶 C (Cat C) 通过影响中性粒细胞丝氨酸蛋白酶 (NSP) 的激活参与炎症和免疫调节。因此，组织蛋白酶 C 是治疗 NSP 相关炎症性疾病的一个有吸引力的靶点。在此，从命中发现、结构优化和先导化合物发现三个方面描述了第一个强效“非肽基非共价组织蛋白酶C抑制剂”的完整发现过程。从hit 14开始，全面开展了基于结构的优化和构效关系研究，发现先导化合物54在体内和体外均是一种有效的类药组织蛋白酶C抑制剂。此外，化合物54 （与组织蛋白酶 C Enz IC 50 = 57.4 nM）在慢性阻塞性肺病动物模型中表现出有效的抗炎活性。这些结果证实了非肽基和非共价衍生物可以用作有效的组织蛋白酶C抑制剂，并鼓励我们在此发现的基础上继续进一步的药物发现。
• Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors
  作者：Weijie Hou、Huan Sun、Yongfen Ma、Chunyan Liu、Zhiyuan Zhang

  DOI：10.1021/acs.jmedchem.9b00631

  日期：2019.6.27

  irreversible inhibitor WZ4002 also functioned as a low micromolar inhibitor of cathepsin C (CatC), a promising target for the treatment of numerous inflammatory and autoimmune diseases. Building on from this discovery, and following structure-activity relationship investigations guided by computational modeling, a novel series of pyridine scaffold compounds were developed as irreversible CatC inhibitors, further

  在将生物化学转化为基于化学活性的蛋白质谱分析（BTC-ABPP）方法的过程中，我们意外地发现，表皮生长因子受体不可逆抑制剂WZ4002还起组织蛋白酶C（CatC）的低微摩尔抑制剂的作用。治疗多种炎性和自身免疫性疾病的靶标。在这一发现的基础上，并在以计算模型为指导的结构-活性关系研究之后，开发了一系列新型的吡啶骨架化合物作为不可逆的CatC抑制剂，进一步鉴定出了高效的，选择性的抑制剂22，该抑制剂表现出良好的代谢稳定性和口服生物利用度。体内研究表明，化合物22清楚地显示出抑制CatC的能力，因此导致骨髓和血液中下游中性粒细胞丝氨酸蛋白酶的有效抑制。化合物22的总体优异特性使其成为进一步临床前研究的有趣候选物。